DIAGENS-B (02526) saw its share price climb as much as 14% in early trading on Thursday, last changing hands up 7.25% at HK$509, with turnover reaching HK$74.13 million. The move comes after the company announced a framework cooperation agreement targeting the core theme of "medical data assetization".

The agreement, signed on September 11, was inked between DIAGENS-B and Zhejiang Anzhen'er Medical Artificial Intelligence Technology Co., Ltd. (Anzhen'er), and covers collaboration across medical imaging AI, grassroots imaging cloud services, and medical data products. The partnership will run for a three-year term commencing from the signing date. Both parties plan to combine DIAGENS-B's iMedImage® multimodal medical imaging capabilities with Anzhen'er's proprietary resources to build a provincial-level "digital imaging" capability foundation, covering pre-consultation guidance, preliminary imaging screening, and report interpretation, with the goal of establishing a benchmark application for provincial-level large medical models.

The two companies intend to jointly develop high-quality medical datasets, AI training corpora, and research analysis products. In essence, this involves transforming fragmented imaging data into standardized, compliant, and reusable "data products". DIAGENS-B has previously accumulated over 28.95 million high-quality annotated images and built a collaboration network spanning 99 hospitals, providing a strong foundation for this initiative and helping elevate medical data from mere "stored files" to value-generating assets. Looking ahead, as the cooperation gradually takes effect, the company's long-term platform value as a leading Hong Kong-listed medical imaging AI player is expected to continue unlocking.